Gene increases effectiveness of drugs used to fight cancer and allows reduction in dosage

Nov 24, 2009
This image shows the effect of gene therapy combined with cytotoxic agents in E spheroids derived from breast cancer cell line MCF-7. A. Control; B. Doxorubicin 10nm, C. Paclitaxel 10nm, D. Docetaxel 10nm, combined with gene E. Credit: University of Granada

Researchers at the University of Granada, Spain, have found a suicide gene, called 'gene E', which leads to the death of tumour cells derived from breast, lung and colon cancer, and prevents their growth. The importance of this new gene is that its use to fight cancer can reduce the potent drugs that are currently used, so that could mean more effective treatment for cancer.

This research was conducted by Ana Rosa Rama Ballesteros, from the Department of Anatomy and Human Embryology at the University of Granada, and directed by professors Antonia Aránega Jimenez, José Carlos Prados Salazar and Consolación Melguizo Alonso. Its aim was to study the possibility of reducing the dosage of drugs currently administered to cancer patients using combination therapy with suicide gene E.

Scientists from the UGR have shown that the bacteriophage phiX174 killer gene called E, can be used to induce death in tumour cells. So far, attempts to use many chemotherapeutic (cytotoxic) agents similar to the E gene have shown severe limitations resulting from their toxicity and their poor affinity with the tumour.

Advantages of gene therapy

As Ana Rosa Rama explains, chemotherapy, radiotherapy and surgery show at present "limited" results in advanced stages of cancer. "That is why it is urgent to find new therapies, and has emerged as a potentially powerful therapeutic platform." Her work has shown that "it is possible to use gene therapy as an aid to chemotherapy, improving its results when it comes to attacking cancer, thus allowing the dosage of agents to be reduced and contributing to a reduction in side effects for the patient."

In order to understand how the E gene works, the researchers conducted studies using various techniques. The results indicate that the E gene's mechanism of action is to induce apoptosis (cell death), possibly through mitochondrial injury.

Therefore, they stress that "this new E gene appears as an ideal candidate to be transfected into tumour cells in order to induce apoptosis, possibly through mitochondrial activation, and to increase the sensitivity of these cells to the action of the drug developed specifically to act on them."

The results of this research suggest the possibility of reducing the concentration of chemotherapeutic agents in current use with cancer patients. Thus, in lung cancer cell line A-549, scientists from the UGR achieved a 14% inhibition of tumour growth and reduced by 100 times the dose of Paclitaxel agent when it was combined with gene E. In the case of colon cancer, the results were similar. However, the most relevant fact was found in the cell line MCF-7, in which the dose of the chemotherapeutic agent, doxorubicin, was reduced by 100 times, reaching up to a 21% greater inhibition of tumour proliferation when combined with gene E. Currently, researchers from the UGR are in the process of obtaining a patent for gene E.

Source: University of Granada

Explore further: New cancer vaccine approach directly targets dendritic cells

add to favorites email to friend print save as pdf

Related Stories

New target for cancer therapy identified

Sep 21, 2006

A new target for cancer therapy has been identified by Monash University scientists investigating the cell signalling pathways that turn on a gene involved in cancer development.

Recommended for you

Survival hope for melanoma patients thanks to new vaccine

3 hours ago

(Medical Xpress)—University of Adelaide researchers have discovered that a new trial vaccine offers the most promising treatment to date for melanoma that has spread, with increased patient survival rates and improved ability ...

New clinical trial launched for advance lung cancer

6 hours ago

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer – marking a new era of research into personalised medicines ...

User comments : 0

More news stories

Bionic ankle 'emulates nature'

These days, Hugh Herr, an associate professor of media arts and sciences at MIT, gets about 100 emails daily from people across the world interested in his bionic limbs.

Smoking's toll on mentally ill analyzed

Those in the United States with a mental illness diagnosis are much more likely to smoke cigarettes and smoke more heavily, and are less likely to quit smoking than those without mental illness, regardless ...

Net neutrality balancing act

Researchers in Italy, writing in the International Journal of Technology, Policy and Management have demonstrated that net neutrality benefits content creator and consumers without compromising provider innovation nor pr ...